Drug formulation for cell and tissue delivery
Tecrea Ltd has developed Nanocin as a platform technology for enhanced cell and tissue delivery. Click HERE to read more about Nanocin. The text below provides useful background information about using GMP grade Nanocin for clinical translation.
New drug development is both costly and time consuming. Costing around $1.3 billion and taking between 10-17 years before reaching the market (1-3). As a result of such market forces, pharmaceutical companies are looking for cost-effective and reduced-risk strategies for developing drug products and protecting existing products from competition as well as extending their patent protection time (5). Developing a new formulation or indication for already known drugs can be considered an appealing strategy for drug developers.
‘Reformulation’ is the development of different formulations for the same pharmaceutical drug(6), whereas ‘repositioning’ is the process of finding a new therapeutic use for an already known drug (7). Both are mainstream strategies in drug development (5, 7) and both appear more cost effective.
Nanocin™ is a drug reformulation platform developed by Tecrea. The core polymer was first synthesised over 80 years ago and can currently be found in a range of over the counter and off the shelf human health and well being products/ Products such as eye drops, wound dressings, body sprays and hand wash to name a few. As such it has a very good and long safety track record.
Our discovery, which is the subject of multiple patent applications, was that Nanocin forms nanoparticles with a range of molecular cargos including DNA, RNA, small molecules, proteins, peptides and natural products. The basic formulation then massively enhances their penetration into cells and tissues. We are already exploring how Nanocin™-GMP can be used to take oral and IV formulated drugs for topical administration in disease settings effecting the skin, lungs, eyes, ears and gut.
We are seeking commercial partners to work with us to help commercially exploit this exciting and innovative finding. We aim to bring our technology nanotechnology to patients in a range of settings and to this end we have already out-licensed the platform in discrete areas of research to both large and small pharma partners.
Reformulations are generally considered to create a disproportionate amount of value considering their cost
Typical cost of life-cycle management strategy
Perceived effectiveness of LCM strategy(5=”highlt effective”)
1. Li YY, Jones SJM. Drug repositioning for personalized medicine. Genome Med. 2012;4:27.
2. Lekka E, Deftereos SN, Persidis A, Persidis A, Andronis C. Literature analysis for systematic drug repurposing: a case study from Biovista. Drug Discov Today Ther Strateg. 2012;8:103 8.
3. Persidis A. The benefits of drug repositioning. Drug Discov World. 2011;12:9 12.
4. Smith RB. Repositioned drugs: integrating intellectual property and regulatory strategies. Drug Discov Today Ther Strateg. 2011;8:131 7.
5. Business Insights reports. Successful strategies for drug repo- sitioning: low-risk approaches to indication expansion and lifecycle extension for established molecules. London (UK): Business Insights; 2011, 101 p. Report No.: BI00050 002.
6. Padhy BM, Gupta YK. Drug repositioning: re-investigating existing drugs for new therapeutic indications. J Postgrad Med. 2011;57:153 60.